- Levi & Korsinsky is investigating Procept BioRobotics over statements tied to a USD 325.5 million revenue target that was followed by reported revenue of USD 308.1 million.
- The firm said CFO Kevin Waters reaffirmed the revenue target and referenced handpiece average selling prices of about USD 3,200.
- According to the investigation notice, Procept had implemented a pricing initiative that removed bulk-purchase discounts, which the firm said reduced realized average selling prices.
- The notice said the revenue shortfall was followed by a share-price drop of more than 15%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190900PRIMZONEFULLFEED9674784) on March 19, 2026, and is solely responsible for the information contained therein.
Comments